Vistagen Therapeutics, Inc. Common Stock (VTGN) Stock Price

VTGNStock

$0.25−92.31%52W

Market Cap$11.02M

P/E—

PEG Ratio—

Div yield—

Beta0.44

VTGN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-63.97%

Price vs S&P 500 (4W)1.67%

VGM Score33.20

Book Value / Share (Quarterly)$0.90

P/TBV (Annual)8.03x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-24.07%

Cash Flow / Share (Quarterly)$-1.68

Price vs S&P 500 (YTD)-75.13%

Net Profit Margin (TTM)-5487.01%

EPS (TTM)$-1.85

10-Day Avg Trading Volume0.91M

EPS Excl Extra (TTM)$-1.85

Revenue Growth (5Y)3.09%

EPS (Annual)$-1.83

ROI (Annual)-195.66%

Net Profit Margin (5Y Avg)-4955.68%

Cash / Share (Quarterly)$1.15

Revenue Growth QoQ (YoY)29.49%

ROA (Last FY)-143.49%

Revenue Growth TTM (YoY)15.28%

EBITD / Share (TTM)$-1.89

ROE (5Y Avg)-171.68%

Operating Margin (TTM)-5678.74%

Cash Flow / Share (Annual)$-1.68

P/B Ratio0.33x

P/B Ratio (Quarterly)0.64x

Net Income / Employee (Annual)$-1,181,100

EV / Revenue (TTM)-15.04x

Net Interest Coverage (TTM)-2458.00x

ROA (TTM)-105.79%

EPS Incl Extra (Annual)$-1.83

Current Ratio (Annual)3.67x

Quick Ratio (Quarterly)3.55x

3-Month Avg Trading Volume3.15M

52-Week Price Return-92.31%

Revenue / Employee (TTM)$21,500

Tangible BV / Share (Quarterly)$2.97

P/S Ratio (Annual)9.13x

Asset Turnover (Annual)0.03x

52-Week High$5.14

Operating Margin (5Y Avg)-5250.74%

EPS Excl Extra (Annual)$-1.83

CapEx CAGR (5Y)-11.62%

Tangible BV CAGR (5Y)11.80%

26-Week Price Return-52.72%

Quick Ratio (Annual)3.55x

13-Week Price Return-61.73%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.67x

Enterprise Value$-19.10M

Revenue / Share Growth (5Y)-38.54%

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-43.33%

Revenue / Employee (Annual)$21,500

Pretax Margin (Annual)-5490.78%

Cash / Share (Annual)$1.15

3-Month Return Std Dev163.88%

Net Income / Employee (TTM)$-1,181,100

ROE (Last FY)-196.19%

Net Interest Coverage (Annual)-5.41x

EPS Basic Excl Extra (Annual)$-1.83

Receivables Turnover (TTM)4.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.85

ROI (TTM)-131.72%

P/S Ratio (TTM)9.13x

Pretax Margin (5Y Avg)-4955.21%

Revenue / Share (Annual)$0.03

Tangible BV / Share (Annual)$1.65

Price vs S&P 500 (52W)-110.62%

Year-to-Date Return-63.17%

5-Day Price Return0.74%

EPS Normalized (Annual)$-1.83

ROA (5Y Avg)-114.61%

Net Profit Margin (Annual)-5491.33%

Month-to-Date Return1.16%

Cash Flow / Share (TTM)$-4.52

EBITD / Share (Annual)$-1.89

Operating Margin (Annual)-5683.69%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-170.78%

LT Debt / Equity (Quarterly)0.02x

EPS Basic Excl Extra (TTM)$-1.85

P/TBV (Quarterly)2.72x

P/B Ratio (Annual)0.64x

Pretax Margin (TTM)-5486.46%

Book Value / Share (Annual)$0.90

Price vs S&P 500 (13W)-64.53%

Beta0.44x

Revenue / Share (TTM)$0.03

ROE (TTM)-133.02%

52-Week Low$0.20

gGradeC

mGradeF

vgmGradeD

VTGN Earnings Surprise History

Q2 25-0.47est. -0.44

Q3 25-0.54est. -0.44

Q4 25-0.45est. -0.48

Q1 26-0.37est. -0.27

Q2 26-0.30est. -0.36

VTGN Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

2.50

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
VTGNVistagen Therapeutics, Inc. Common Stock	—	C	F	$0.25
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Vistagen Therapeutics, Inc. Common Stock

Vistagen Therapeutics is a biotechnology company developing novel therapies for psychiatric and neurological disorders using proprietary nose-to-brain delivery technology. The company's targeted approach leverages neurocircuitry insights to potentially create unique treatment pathways for conditions currently lacking effective options.